Andrea K. Mccollum

Array ( [id] => 16991871 [patent_doc_number] => 20210230291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => TARGETED ENGINEERED INTERFERON AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/133782 [patent_app_country] => US [patent_app_date] => 2020-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17133782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16871515 [patent_doc_number] => 20210164982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => PHARMACEUTICAL USE OF ACTININ-4 INVOLVED IN INDUCTION OF CERVICAL CANCER [patent_app_type] => utility [patent_app_number] => 17/123349 [patent_app_country] => US [patent_app_date] => 2020-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17123349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18278991 [patent_doc_number] => 20230094463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/777573 [patent_app_country] => US [patent_app_date] => 2020-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54078 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050751 [patent_doc_number] => 20210260185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => Combination Therapies and Uses for Treatment of Demyelinating Disorders [patent_app_type] => utility [patent_app_number] => 17/107554 [patent_app_country] => US [patent_app_date] => 2020-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37895 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17107554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720138 [patent_doc_number] => 20210087285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => USE OF ANTI-IL-36R ANTIBODIES FOR TREATMENT OF GENERALIZED PUSTULAR PSORIASIS [patent_app_type] => utility [patent_app_number] => 17/101126 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720138 [patent_doc_number] => 20210087285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => USE OF ANTI-IL-36R ANTIBODIES FOR TREATMENT OF GENERALIZED PUSTULAR PSORIASIS [patent_app_type] => utility [patent_app_number] => 17/101126 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093125 [patent_doc_number] => 20220411466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => METHOD TO INCREASE ANTIBODY YIELD DURING ION EXCHANGE CHROMATOGRAPHY [patent_app_type] => utility [patent_app_number] => 17/777385 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19311609 [patent_doc_number] => 12037412 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Anti-KLK5 antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 16/950418 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 69 [patent_figures_cnt] => 175 [patent_no_of_words] => 59905 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673138 [patent_doc_number] => 20210061901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => USE OF ANTI-IL-36R ANTIBODIES FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE [patent_app_type] => utility [patent_app_number] => 17/095882 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17095882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129165 [patent_doc_number] => 12371467 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => T cell receptors targeting PIK3CA mutations and uses thereof [patent_app_type] => utility [patent_app_number] => 17/095288 [patent_app_country] => US [patent_app_date] => 2020-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 28 [patent_no_of_words] => 26942 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17095288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126242 [patent_doc_number] => 20210301010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => METHODS FOR TREATING ATOPIC DERMATITIS AND RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/084957 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671367 [patent_doc_number] => 20210060130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR RELIEVING ANTICANCER DRUG RESISTANCE AND ENHANCING SENSITIVITY OF ANTICANCER DRUG [patent_app_type] => utility [patent_app_number] => 17/085480 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109905 [patent_doc_number] => 20230002785 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => MRNA-ENCODED ANTIBODIES FOR CONTRACEPTION [patent_app_type] => utility [patent_app_number] => 17/772932 [patent_app_country] => US [patent_app_date] => 2020-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11823 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17023534 [patent_doc_number] => 20210247405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => METHODS OF PROGNOSIS AND TREATMENT [patent_app_type] => utility [patent_app_number] => 17/077049 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17077049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720136 [patent_doc_number] => 20210087283 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => FGFR1 AGONISTS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/073498 [patent_app_country] => US [patent_app_date] => 2020-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17073498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18295771 [patent_doc_number] => 20230105457 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => Immunogenic Compounds For Treatment Of Adrenal Cancer [patent_app_type] => utility [patent_app_number] => 17/768757 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -147 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17768757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17096963 [patent_doc_number] => 20210284754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS [patent_app_type] => utility [patent_app_number] => 17/068441 [patent_app_country] => US [patent_app_date] => 2020-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17068441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18620426 [patent_doc_number] => 11753454 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => IL-15 and IL-15R\alpha sushi domain based immunocytokines [patent_app_type] => utility [patent_app_number] => 17/068628 [patent_app_country] => US [patent_app_date] => 2020-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14119 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17068628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034201 [patent_doc_number] => 20240084016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => STABLE FORMULATION OF INTEGRIN ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/766823 [patent_app_country] => US [patent_app_date] => 2020-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5196 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17068624 [patent_doc_number] => 20210270839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => SYSTEMS AND METHODS FOR ANALYZING PERSISTENT HOMEOSTATIC PERTURBATIONS [patent_app_type] => utility [patent_app_number] => 17/067400 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067400 [rel_patent_id] =>[rel_patent_doc_number] =>)